Clinical Trial

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

Study acronym: EUREkA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 8, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Trial Details
NCT Number NCT07159750
Lead Sponsor Hospital Universitari Vall d'Hebron Research Institute
Conditions Migraine, Episodic Migraine, Chronic Migraine, Headache
Enrollment 700 participants
Start Date 2024-01-02
Primary Completion 2026-01 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-08